A listing of in-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high riskhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) afterd to other parts of the body. This study will also …
The purpose of this registry is to collect safety and performance data on all commerciallyvailable Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard. Data will be collected both retrospectively and prospectively.
The primary purpose of the Research Sample Repository is to make blood samples available forh studies related to histocompatibility and hematopoietic cell transplantation (HCT)her cellular therapy. Representatives of participating centers and investigators or research groups may requesth samples contained in the Research Sample Repository for the purpose ofducting research including: …
This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma.
This randomized phase II trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body.
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).